EDI048

Overview

EDI048 is an orally active, gut-restricted parasiticidal agent. EDI048 specifically binds to the ATP-binding site of Cryptosporidium phosphatidylinositol 4-kinase (CpPI (4) K), blocks parasite membrane biogenesis, arrests the pathogen at the schizont stage, and thus irreversibly clears the infection . EDI048 is rapidly converted to an inactive carboxylic acid metabolite via hepatic first-pass metabolism, with extremely low systemic exposure, good safety profile, and no cardiotoxicity, genotoxicity or off-target effects. EDI048 is used in studies of intestinal cryptosporidiosis in children.

Application

Products | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Parasitic Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Metabolic Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PI4K | Products > Signaling Pathways > Parasite

Product Information

• Catalog No.: HY-156685
• CAS No.: 2767264-57-1
• Molecular Formula: C25H21ClN4O4
• Molecular Weight: 476.91
• Purity: 99.86%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution
• Availability: In-stock

Source

Original product source